Similar articles

• Factor VIII and factor IX inhibitors in haemophiliacs.

  Ljung R, Petrini P, Lindgren AC, Tengborn L, Nilsson IM. Ljung R, et al. Lancet. 1992 Jun 20;339(8808):1550. Lancet. 1992. PMID: 1351234 No abstract available.
• Effect of frequent factor VIII replacement on the level of factor VIII antibodies in haemophiliacs.

  Rizza CR, Matthews JM. Rizza CR, et al. Br J Haematol. 1982 Sep;52(1):13-24. doi: 10.1111/j.1365-2141.1982.tb03857.x. Br J Haematol. 1982. PMID: 6810911 No abstract available.
• Zero incidence of inhibitors in previously untreated patients who received intermediate purity factor VIII concentrate or factor IX complex.

  Schimpf K, Schwarz P, Kunschak M. Schimpf K, et al. Thromb Haemost. 1995 Mar;73(3):553-5. Thromb Haemost. 1995. PMID: 7667845 No abstract available.
• [Inhibitors and "bypass" therapy in hemophilia].

  Fukutake K, Fukutake K. Fukutake K, et al. Nihon Rinsho. 1981;39(12):3688-99. Nihon Rinsho. 1981. PMID: 6803034 Review. Japanese. No abstract available.
• Inhibitor antibodies to factor VIII and factor IX: management.

  Lusher JM. Lusher JM. Semin Thromb Hemost. 2000;26(2):179-88. doi: 10.1055/s-2000-9821. Semin Thromb Hemost. 2000. PMID: 10919411 Review.